Home  »  Hot Stocks   »  Orphazyme A/S (ORPH): Skating on Thin Ice? We Know...

Orphazyme A/S (ORPH): Skating on Thin Ice? We Know the Answer

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Orphazyme A/S (NASDAQ:ORPH) went up by 9.87% from its latest closing price compared to the recent 1-year high of $77.77. The company’s stock price has collected -5.41% of loss in the last five trading sessions. Press Release reported on 01/07/22 that CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference

Is It Worth Investing in Orphazyme A/S (NASDAQ :ORPH) Right Now?

ORPH currently public float of 34.45M and currently shorts hold a 0.30% ratio of that float. Today, the average trading volume of ORPH was 1.35M shares.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


ORPH’s Market Performance

ORPH stocks went down by -5.41% for the week, with a monthly drop of -12.19% and a quarterly performance of -38.44%, while its annual performance rate touched -78.34%. The volatility ratio for the week stands at 6.61% while the volatility levels for the past 30 days are set at 7.75% for Orphazyme A/S. The simple moving average for the period of the last 20 days is -7.37% for ORPH stocks with a simple moving average of -55.62% for the last 200 days.

Analysts’ Opinion of ORPH

BofA Securities, on the other hand, stated in their research note that they expect to see ORPH reach a price target of $5, previously predicting the price at $13. The rating they have provided for ORPH stocks is “Underperform” according to the report published on March 30th, 2021.

Guggenheim gave a rating of “Buy” to ORPH, setting the target price at $27 in the report published on October 26th of the previous year.

ORPH Trading at -23.24% from the 50-Day Moving Average

After a stumble in the market that brought ORPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.85% of loss for the given period.

Volatility was left at 7.75%, however, over the last 30 days, the volatility rate increased by 6.61%, as shares sank -10.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.02% lower at present.

During the last 5 trading sessions, ORPH fell by -5.41%, which changed the moving average for the period of 200-days by -72.16% in comparison to the 20-day moving average, which settled at $2.63. In addition, Orphazyme A/S saw 1.66% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for ORPH

The total capital return value is set at -148.19, while invested capital returns managed to touch -164.77. Equity return is now at value -251.20, with -160.50 for asset returns.

Based on Orphazyme A/S (ORPH), the company’s capital structure generated 11.40 points at debt to equity in total, while total debt to capital is 10.23. Total debt to assets is 8.60, with long-term debt to equity ratio resting at 5.43. Finally, the long-term debt to capital ratio is 4.88.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of -9.71, with the company’s debt to enterprise value settled at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.70.

Leave a Comment

Your email address will not be published. Required fields are marked *

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam